PMC:7228307 / 61606-62087
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1246 | 164-168 | Gene | denotes | FcγR | Gene:2213 |
1247 | 348-352 | Gene | denotes | FcγR | Gene:2213 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T458 | 263-276 | Body_part | denotes | immune system | http://purl.org/sig/ont/fma/fma9825 |
T459 | 362-370 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T32 | 263-276 | Body_part | denotes | immune system | http://purl.obolibrary.org/obo/UBERON_0002405 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T998 | 24-26 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T999 | 164-166 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
T1000 | 263-276 | http://purl.obolibrary.org/obo/UBERON_0002405 | denotes | immune system |
T1001 | 348-350 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T75881 | 228-236 | Chemical | denotes | effector | http://purl.obolibrary.org/obo/CHEBI_35224 |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T266 | 472-480 | http://purl.obolibrary.org/obo/OGMS_0000031 | denotes | diseases |
LitCovid-sample-Enju
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T644 | 0-6 | RB | denotes | Rather |
T645 | 7-11 | IN | denotes | than |
T646 | 12-15 | CD | denotes | one |
T647 | 16-20 | NN | denotes | type |
T648 | 21-23 | IN | denotes | of |
T649 | 24-26 | NN | denotes | Fc |
T650 | 27-29 | TO | denotes | to |
T651 | 30-37 | VB | denotes | conquer |
T652 | 38-41 | DT | denotes | all |
T653 | 41-42 | -COMMA- | denotes | , |
T654 | 43-46 | DT | denotes | the |
T655 | 47-55 | JJ | denotes | combined |
T656 | 56-59 | NN | denotes | use |
T657 | 60-62 | IN | denotes | of |
T658 | 63-76 | RB | denotes | appropriately |
T659 | 77-85 | VBN | denotes | selected |
T660 | 86-90 | NNS | denotes | mAbs |
T661 | 91-96 | WP-DOLLAR- | denotes | whose |
T662 | 97-107 | JJ | denotes | individual |
T663 | 108-118 | NNS | denotes | components |
T664 | 119-122 | VBP | denotes | are |
T665 | 123-131 | VBN | denotes | enhanced |
T666 | 132-135 | IN | denotes | for |
T667 | 136-139 | DT | denotes | the |
T668 | 140-150 | NN | denotes | engagement |
T669 | 151-153 | IN | denotes | of |
T670 | 154-163 | JJ | denotes | different |
T671 | 164-168 | NN | denotes | FcγR |
T672 | 169-176 | NNS | denotes | members |
T673 | 177-180 | MD | denotes | may |
T674 | 181-188 | VB | denotes | utilize |
T675 | 189-197 | JJ | denotes | multiple |
T676 | 198-208 | NNS | denotes | components |
T677 | 209-211 | IN | denotes | of |
T678 | 212-215 | DT | denotes | the |
T679 | 216-224 | NN | denotes | spectrum |
T680 | 225-227 | IN | denotes | of |
T681 | 228-236 | NN | denotes | effector |
T682 | 237-246 | NNS | denotes | responses |
T683 | 247-249 | IN | denotes | on |
T684 | 250-255 | NN | denotes | offer |
T685 | 256-258 | IN | denotes | by |
T686 | 259-262 | DT | denotes | the |
T687 | 263-269 | JJ | denotes | immune |
T688 | 270-276 | NN | denotes | system |
T689 | 278-282 | JJ | denotes | Such |
T690 | 283-293 | NN | denotes | “next‐gen” |
T691 | 294-303 | NNS | denotes | biologics |
T692 | 304-308 | MD | denotes | will |
T693 | 309-314 | VB | denotes | begin |
T694 | 315-317 | TO | denotes | to |
T695 | 318-325 | VB | denotes | realize |
T696 | 326-329 | DT | denotes | the |
T697 | 330-334 | JJ | denotes | full |
T698 | 335-344 | NN | denotes | potential |
T699 | 345-347 | IN | denotes | of |
T700 | 348-361 | JJ | denotes | FcγR‐mediated |
T701 | 362-370 | NN | denotes | antibody |
T702 | 371-377 | JJ | denotes | immune |
T703 | 378-390 | NNS | denotes | therapeutics |
T704 | 391-394 | CC | denotes | and |
T705 | 395-400 | VB | denotes | offer |
T706 | 401-417 | JJ | denotes | transformational |
T707 | 418-424 | NN | denotes | change |
T708 | 425-428 | IN | denotes | for |
T709 | 429-432 | DT | denotes | the |
T710 | 433-442 | NN | denotes | treatment |
T711 | 443-445 | IN | denotes | of |
T712 | 446-457 | JJ | denotes | intractable |
T713 | 458-461 | CC | denotes | and |
T714 | 462-471 | JJ | denotes | incurable |
T715 | 472-480 | NNS | denotes | diseases |
R703 | T688 | T685 | arg2Of | system,by |
R704 | T688 | T686 | arg1Of | system,the |
R705 | T688 | T687 | arg1Of | system,immune |
R706 | T691 | T689 | arg1Of | biologics,Such |
R707 | T691 | T690 | arg1Of | biologics,“next‐gen” |
R708 | T691 | T692 | arg1Of | biologics,will |
R709 | T693 | T692 | arg2Of | begin,will |
R660 | T674 | T644 | arg1Of | utilize,Rather |
R661 | T644 | T645 | arg1Of | Rather,than |
R662 | T647 | T645 | arg2Of | type,than |
R663 | T647 | T646 | arg1Of | type,one |
R664 | T647 | T648 | arg1Of | type,of |
R665 | T649 | T648 | arg2Of | Fc,of |
R666 | T651 | T650 | arg1Of | conquer,to |
R667 | T647 | T650 | modOf | type,to |
R668 | T652 | T651 | arg2Of | all,conquer |
R669 | T674 | T653 | arg1Of | utilize,"," |
R670 | T656 | T654 | arg1Of | use,the |
R671 | T656 | T655 | arg1Of | use,combined |
R672 | T656 | T657 | arg1Of | use,of |
R673 | T660 | T657 | arg2Of | mAbs,of |
R674 | T659 | T658 | arg1Of | selected,appropriately |
R675 | T660 | T659 | arg1Of | mAbs,selected |
R676 | T663 | T661 | arg1Of | components,whose |
R677 | T660 | T661 | arg2Of | mAbs,whose |
R678 | T663 | T662 | arg1Of | components,individual |
R679 | T663 | T664 | arg1Of | components,are |
R680 | T665 | T664 | arg2Of | enhanced,are |
R681 | T663 | T665 | arg2Of | components,enhanced |
R682 | T665 | T666 | arg1Of | enhanced,for |
R683 | T668 | T666 | arg2Of | engagement,for |
R684 | T668 | T667 | arg1Of | engagement,the |
R685 | T668 | T669 | arg1Of | engagement,of |
R686 | T672 | T669 | arg2Of | members,of |
R687 | T672 | T670 | arg1Of | members,different |
R688 | T672 | T671 | arg1Of | members,FcγR |
R689 | T656 | T673 | arg1Of | use,may |
R690 | T674 | T673 | arg2Of | utilize,may |
R691 | T656 | T674 | arg1Of | use,utilize |
R692 | T676 | T674 | arg2Of | components,utilize |
R693 | T676 | T675 | arg1Of | components,multiple |
R694 | T676 | T677 | arg1Of | components,of |
R695 | T679 | T677 | arg2Of | spectrum,of |
R696 | T679 | T678 | arg1Of | spectrum,the |
R697 | T679 | T680 | arg1Of | spectrum,of |
R698 | T682 | T680 | arg2Of | responses,of |
R699 | T682 | T681 | arg1Of | responses,effector |
R700 | T679 | T683 | arg1Of | spectrum,on |
R701 | T684 | T683 | arg2Of | offer,on |
R702 | T674 | T685 | arg1Of | utilize,by |
R710 | T691 | T693 | arg1Of | biologics,begin |
R711 | T704 | T693 | arg2Of | and,begin |
R712 | T704 | T694 | arg1Of | and,to |
R713 | T691 | T695 | arg1Of | biologics,realize |
R714 | T698 | T695 | arg2Of | potential,realize |
R715 | T698 | T696 | arg1Of | potential,the |
R716 | T698 | T697 | arg1Of | potential,full |
R717 | T698 | T699 | arg1Of | potential,of |
R718 | T703 | T699 | arg2Of | therapeutics,of |
R719 | T703 | T700 | arg1Of | therapeutics,FcγR‐mediated |
R720 | T703 | T701 | arg1Of | therapeutics,antibody |
R721 | T703 | T702 | arg1Of | therapeutics,immune |
R722 | T695 | T704 | arg1Of | realize,and |
R723 | T705 | T704 | arg2Of | offer,and |
R724 | T691 | T705 | arg1Of | biologics,offer |
R725 | T707 | T705 | arg2Of | change,offer |
R726 | T707 | T706 | arg1Of | change,transformational |
R727 | T705 | T708 | arg1Of | offer,for |
R728 | T710 | T708 | arg2Of | treatment,for |
R729 | T710 | T709 | arg1Of | treatment,the |
R730 | T710 | T711 | arg1Of | treatment,of |
R731 | T715 | T711 | arg2Of | diseases,of |
R732 | T715 | T712 | arg1Of | diseases,intractable |
R733 | T712 | T713 | arg1Of | intractable,and |
R734 | T714 | T713 | arg2Of | incurable,and |
R735 | T715 | T714 | arg1Of | diseases,incurable |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
1246 | 164-168 | Gene | denotes | FcγR | Gene:2213 |
1247 | 348-352 | Gene | denotes | FcγR | Gene:2213 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T340 | 0-277 | Sentence | denotes | Rather than one type of Fc to conquer all, the combined use of appropriately selected mAbs whose individual components are enhanced for the engagement of different FcγR members may utilize multiple components of the spectrum of effector responses on offer by the immune system. |
T341 | 278-481 | Sentence | denotes | Such “next‐gen” biologics will begin to realize the full potential of FcγR‐mediated antibody immune therapeutics and offer transformational change for the treatment of intractable and incurable diseases. |
LitCovid-sample-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T29 | 263-276 | Body_part | denotes | immune system | http://purl.obolibrary.org/obo/UBERON_0002405 |
LitCovid-sample-UniProt
Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
---|---|---|---|---|---|
T827 | 330-334 | Protein | denotes | full | https://www.uniprot.org/uniprot/Q8N1N2 |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T457 | 263-276 | Body_part | denotes | immune system | http://purl.org/sig/ont/fma/fma9825 |
T458 | 362-370 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T340 | 0-277 | Sentence | denotes | Rather than one type of Fc to conquer all, the combined use of appropriately selected mAbs whose individual components are enhanced for the engagement of different FcγR members may utilize multiple components of the spectrum of effector responses on offer by the immune system. |
T341 | 278-481 | Sentence | denotes | Such “next‐gen” biologics will begin to realize the full potential of FcγR‐mediated antibody immune therapeutics and offer transformational change for the treatment of intractable and incurable diseases. |